Verona Stock Soars After $200m Placement For COPD Drug
Fundraise Nearly Quadruples Market Cap
Executive Summary
The UK biotech will have no problems funding a Phase III program for its nebulized first-in-class COPD therapy ensifentrine as investors old and new flocked to buy into the stock.
You may also be interested in...
UK Biotechs Look Destined To Remain Bit Players
Another promising British-based company, GW Pharma, has been acquired, this time by mid-sized US player Jazz. Is it a pipedream that a UK biotech could be in a position to pull off a $7bn takeover of its own or does it really not matter?
Itching To Succeed: UNION Buys LEO Pharma’s PDE4 Inhibitor Series
Denmark-based UNION therapeutics has bought LEO Pharma’s PDE4 inhibitor compound series for use in developing treatments for psoriasis and atopic dermatitis.
AstraZeneca's Imfinzi/Tremelimumab Combo Conquers HIMALAYA
After the combination's success in the non-small cell lung cancer POSEIDON study, AstraZeneca's Imfinzi and tremelimumab could now be on the way to approval as a first-line treatment for hepatocellular carcinoma.